10$-50$ target đŻ
The recent annual numbers from Exagen Inc. show promising results, with revenues exceeding forecasts by 4.4% and statutory losses per share coming in 4.4% smaller than expected. Following these results, analysts have adjusted their earnings model, with revenue forecasts for 2024 now at US$54.2 million, reflecting a 3.1% improvement compared to the last 12 months. Despite the steady losses expected, the consensus price target remains unchanged at US$5.50 per share, indicating that the business is performing in line with estimates. However, there are varying analyst views, with price targets ranging from US$5.00 to US$7.00 per share. It's worth noting that while Exagen's revenue growth is projected to slow down, the wider industry is expected to grow faster. This suggests that while Exagen's performance may be steady, it may lag behind industry peers in terms of growth.
The recent annual numbers from Exagen Inc. show promising results, with revenues exceeding forecasts by 4.4% and statutory losses per share coming in 4.4% smaller than expected. Following these results, analysts have adjusted their earnings model, with revenue forecasts for 2024 now at US$54.2 million, reflecting a 3.1% improvement compared to the last 12 months. Despite the steady losses expected, the consensus price target remains unchanged at US$5.50 per share, indicating that the business is performing in line with estimates. However, there are varying analyst views, with price targets ranging from US$5.00 to US$7.00 per share. It's worth noting that while Exagen's revenue growth is projected to slow down, the wider industry is expected to grow faster. This suggests that while Exagen's performance may be steady, it may lag behind industry peers in terms of growth.